declares having received consulting honoraria from Amgen, Boehringer Ingelheim, Merck, Pfizer, Aegerion, Novartis, Sanofi, Takeda, Novo Nordisk and Bayer, and research grants from British Heart Foundation, MRC (UK), NIHR, PHE, MSD, Pfizer, Aegerion, Colgate and Roche
Do not simply resume using potentially compromised medication without professional consultation, as this could result in inadequate disease control
At the time we first started pursuing this litigation, Mounjaro was probably the only label that listed something related to gastroparesis, but it is in no way adequate
Resmetirom (MGL-3196) for the treatment of non-alcoholic steatohepatitis: a multicentre, randomised, double-blind, placebo-controlled, phase 2 trial
Carbonneau, J